Slide 1: Presentation Q4(19)
Presentation Q4(19) Jonas Jarvius, CEO Anders Lundin, CFO STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea in brief
Headquarters & production facilities in Uppsala Q-linea in brief Introduction to the company • Q-linea is developing disruptive solutions for Lead product ASTar® faster infectious disease diagnostics • First product is ASTar with a initial focus on blood Introduc5on to the company stream infections
Slide 4: Q-linea's lead product candidate – ASTar® – a modular AST system
Q-linea’s lead product candidate – ASTar® – a modular AST system • Phenotypic AST results in 3 ASTar® offering to 6 hours for blood System Rapid • Answer <45 minutes for e.g. urine • Fully automated • Up to 12 samples analyzed in Simple to use parallel Consumables • Up to 50 samples per day1) Fully-a
Slide 5: ASTar® key highlights vs. competition
ASTar® key highlights vs. competition Disruptive AST analysis 1 Broadest panel coverage Enables both escalation & de-escalation Minimize need for follow-up tests required 2 Broad pathogen coverage Includes both fastidious & non-fastidious bacteria 3 High throughput & Random access Up to 50 pa@ent sa
Slide 6: Key highlights fourth quarter
Key highlights fourth quarter Positive feedback on our product offering during FIS conference 24/7 operation by anyone in the lab. Broad panel & MIC ranges. Possible to handle many sample types. Several ASTar systems under thorough testing Internal evaluation ongoing (total 10 systems). Have receive
Slide 7: Key highlights fourth quarter
Key highlights fourth quarter Solving the problem with a key component progressing very well Together with our supplier we have identified and made corrective actions to the problem. Several systems have been running smoothly for more than two month. We are waiting for additional systems to enter te
Slide 8: Key highlights fourth quarter
Key highlights fourth quarter Increased capacity for internal consumable production Building of the new production facilities is progressing according to plan . 390 sqm ISO8, Class C Clean room, 1 500 sqm in total. Strengthening of our commercial organization in preparation for launch Our first fiel
Slide 9: Key events after the end of the period
Key events after the end of the period Q-linea signs global partnership with Thermo Fisher Scien@fic for commercializa@on of ASTar We share a common market view and agree on how infec@on diagnos@cs can be improved. Thermo Fisher will have exclusive rights to distribute ASTar worldwide and Q-linea can
Slide 10: Income statement fourth quarter
Income statement fourth quarter • Net sales in the fourth quarter amounted to SEK 0.02 million (0.25). • Operating result totalled SEK -62.1 million (-39.0). • The company reported a loss after tax of SEK -62.0 million (-39.4). • Earnings per share amounted to SEK -2.71 (-2.33). Figures in parenthes
Slide 11: Balance sheet at end of fourth quarter
Balance sheet at end of fourth quarter • Cash and cash equivalents amounted to SEK 26.0 million (354.4) • Short-term investments in fixed-income funds and the current portion of non-current assets (listed bonds) 180.5 million (150.0). • Non-current assets, listed bonds SEK 121.0 million (0). Figures
Slide 12: Cash flow statement fourth quarter
Cash flow statement fourth quarter • Cash flow from operating activities SEK -52.1 million (-37.4). • Cash flow from investing activities SEK 57.4 millions (-112.9). • Cash flow from financing activities SEK 1.4 millions (492.4). • Increased cash outflow from operating activities mainly due to a lar
Slide 13: Thank you
Thank you Strictly private and confidential 13